|INDIA: Supreme Court to Hear Dispute on Drug Patents|
by Vikas Bajaj and Andrew Pollack, New York Times
March 6th, 2012
A Swiss drug company, Novartis, will go before the Indian Supreme Court this monnth to fight patent laws that protect the global supply of inexpensive medicines to treat AIDS, cancer and other diseases. The lawsuit - which involves a drug called Gleevec - is being opposed by international aid groups.
|US: Online Age Quiz Is a Window for Drug Makers|
by STEPHANIE CLIFFORD, New York Times
March 25th, 2009
RealAge, promising to help shave years off your age, has become one of the most popular quizzes on the Internet. The test asks 150 questions about lifestyle and family history to assign a “biological age." But then pharmaceutical companies pay RealAge to compile test results of RealAge members and send them marketing messages by e-mail.
|US: High Court Eases Way to Liability Lawsuits|
by Jess Bravin, Wall Street Journal
March 5th, 2009
The Supreme Court said drug makers can be sued in state court over alleged defects, even if the Food and Drug Administration has approved a medication's use. The 6-3 ruling undercuts years of business efforts to block state suits over the safety of products from motorcycle brakes to railway cars.
|SWITZERLAND: Davos Scales Back Glitz|
by Associated Press, New York Times
January 25th, 2009
The economic crisis that emerged out the collapse of securities based on shaky U.S. mortgages poses challenges for the Davos World Economic Forum, an arena that has championed market-driven approaches.
|US: Research Center Tied to Drug Company
by GARDINER HARRIS, The New York Times
November 24th, 2008
Court documents reveal that Dr. Joseph Biederman, a renowned child psychiatrist, pushed Johnson & Johnson to fund a research center whose goal was “to move forward the commercial goals of J&J.”
|US: Radio Host Has Drug Company Ties
by GARDINER HARRIS, The New York Times
November 21st, 2008
An influential psychiatrist who was the host of the popular NPR program “The Infinite Mind” earned at least $1.3 million from 2000 to 2007 giving marketing lectures for drugmakers, income not mentioned on the program.
|US: Eli Lilly settles Zyprexa inquiries in 32 states|
by TOM MURPHY and MARLEY SEAMAN, Associated Press
October 7th, 2008
Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication.
|ARGENTINA: Is GlaxoSmithKline Behaving Badly in Argentina?
by AINA HUNTER, ABC News
September 23rd, 2008
Michaela, a deceased 5 month old, is one of more than 13,000 Argentine children to participate in a clinical study implemented a little more than a year ago by the London-based GlaxoSmithKline, the world's second-largest drug manufacturer.
|US: Judge to Unseal Documents on the Eli Lilly Drug Zyprexa
by MARY WILLIAMS WALSH, The New York Times
September 5th, 2008
A federal judge in Brooklyn decided on Friday to unseal confidential materials about Eli Lilly’s top-selling antipsychotic drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses.
|US: U.S. Drug Ads Questioned
by KEITH J. WINSTEIN and SUZANNE VRANICA, The Wall Street Journal
September 3rd, 2008
Consumer advertising for prescription drugs had a negligible impact on sales of products studied by Harvard Medical School researchers -- in a finding that may confound both advertisers and their opponents.
|US: For Widely Used Drug, Question of Usefulness Is Still Lingering
by ALEX BERENSON, The New York Times
September 1st, 2008
About the only point on which both sides agree is that no one can judge ezetimibe’s safety and benefits for certain without more data, ideally from a clinical trial covering more than 10,000 patients and lasting several years, long enough to show that the drug actually helps patients live longer or avoid heart attacks.
|US: Mannatech Settles Holder Suits
by SUZANNE SATALINE, Wall Street Journal
June 13th, 2008
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.
|US: Researchers Fail to Reveal Full Drug Pay
by GARDINER HARRIS and BENEDICT CAREY, The New York Times
June 8th, 2008
A world-renowned Harvard child psychiatrist whose work has helped fuel an explosion in the use of powerful antipsychotic medicines in children earned at least $1.6 million in consulting fees from drug makers from 2000 to 2007 but for years did not report much of this income to university officials, according to information given Congressional investigators.